Pelvic lymphangioleiomyomatosis treated successfully with everolimus: Two case reports with literature review
Related Experiment Video
Updated: Mar 6, 2026
Surgical Treatment of an Endolymphatic Sac Tumor
Published on: May 26, 2023
Sharjil Wahid1, Ping Chia Chiang, Hao Lun Luo
1Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University Department of Pathology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine Department of Obstetrics and Gynecology, Kaohsiung Medical University Hospital, Kaohsiung Medical University Graduate Institute of Medicine, Center of Excellence for Environmental Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan College of Physicians and Surgeons, Pakistan School of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Background:
Lymphangioleiomyomatosis (LAM) is a rare disease affecting young women caused by abnormal proliferation of smooth muscle-like cells (LAM cells) in the lungs and extrapulmonary sites (extrapulmonary LAM). The objective of this case series is to demonstrate marked regression in 2 cases of retroperitoneal LAM after treatment with everolimus, an mTOR inhibitor.
Methods:
We enrolled 2 cases with large volume, extrapulmonary pelvic LAM, and evaluated them with contrast-enhanced abdominal computed tomographic (CT) scans at presentation and serially during treatment with everolimus. Results were objectively quantified using the Response Evaluation Criteria in Solid Tumors, RECIST, Version 1.1.
Results:
After 12 to 18 months of treatment with everolimus, both patients showed substantial reduction in the volume of their tumors. The first had about 50% regression of the pelvic LAM and renal angiomyolipoma (AML). The second patient had extensive abdomino-pelvic LAM which after treatment showed complete remission. Both patients have not demonstrated disease progression after nearly 4 and 2 years of follow-up, respectively.
Conclusions:
This case series demonstrates the enormous value of mTOR inhibitors (specifically everolimus) in the management of extrapulmonary pelvic LAM, of which there is no effective treatment currently available.
More Related Videos
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017